McLeod Health

Place Sticker Here

Rozanolixizumab-noli (Rystiggo) Treatment Plan Patient Name: ______ DOB: _____ Height (cm): _____ Weight (kg): _____ Allergies: _____ Diagnosis (select one): \square G70.00 Myasthenia Gravis without acute exacerbation \square G70.01 Myasthenia Gravis with acute exacerbation ☐ Other: ICD 10 Code: ______ Diagnosis Description: _____ **Drug Orders:** • Rozanolixizumab (Rystiggo) (J9333) administered via subcutaneous infusion at 20 ml/hr once weekly \square Weight < 50 kg: 420 mg (3 mL) Dose: ☐ Weight 50 kg-100 kg: 560 mg (4 mL) ☐ Weight > 100 kg: 840 mg (6 mL) Order Duration: Six weeks unless otherwise specified (Other:_______) **Standing Orders:** • Monitor patient for 15 minutes following completion of infusion. No flushing of infusion line following infusion completion. • Infusion Reaction Protocol (CPOE-1396) will be activated if any hypersensitivity reaction occurs, including anaphylaxis. Infusion will be stopped and physician notified.

Physician Signature:

Physician Name: _____

Date: _____

Phone:

Pre-Screening Requirements:

• Positive anti-acetylcholine receptor (AChR) or anti-muscle-specific tyroskine kinase (MuSK) antibody

Previous Therapies:

• For new patient referrals, please send history and physical and most recent physician note with completed p	olan
• If patient has previously received Rystiggo at another facility, please provide last date received:	
If patient has previously received another therapy, please provide the name:ast date received:	and the
Insurance/Authorization Information:	
Insurance Type:	
Insurance Authorization Reference Number:	
Date Obtained: Authorization Valid Until:	
Additional Notes:	

Fax completed Treatment Plan with authorization information to McLeod Infusion Services at the number below or call with any questions.

Florence: 843-777-6001 (Fax)

843-777-6195 (Phone)